Can an ANDA sponsor forfeit 180-day market exclusivity for its generic by amending its proposed label?
That appears to be the question at the center of Par Pharmaceutical Inc.’s suit against FDA. The
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?